| pubmed-article:788772 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:788772 | lifeskim:mentions | umls-concept:C0005699 | lld:lifeskim |
| pubmed-article:788772 | lifeskim:mentions | umls-concept:C0023473 | lld:lifeskim |
| pubmed-article:788772 | lifeskim:mentions | umls-concept:C0699040 | lld:lifeskim |
| pubmed-article:788772 | lifeskim:mentions | umls-concept:C0005516 | lld:lifeskim |
| pubmed-article:788772 | lifeskim:mentions | umls-concept:C0439677 | lld:lifeskim |
| pubmed-article:788772 | lifeskim:mentions | umls-concept:C0936012 | lld:lifeskim |
| pubmed-article:788772 | lifeskim:mentions | umls-concept:C0868928 | lld:lifeskim |
| pubmed-article:788772 | lifeskim:mentions | umls-concept:C1518071 | lld:lifeskim |
| pubmed-article:788772 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:788772 | pubmed:dateCreated | 1976-12-30 | lld:pubmed |
| pubmed-article:788772 | pubmed:abstractText | Fourteen cases of philadelphia chromosome (Ph1) positive chronic myeloid leukaemia in blast transformation have been investigated using cell surface markers. Morphologically eight cases were lymphoid and the remainder myeloid in appearance. All cases were negative with surface markers for thymocytes and T and B lymphocytes. Five of the lymphoid cases reacted with an antiserum specific for acute lymphoid leukaemia )ALL) of non-T non-B type and were also weakly reactive with a lymphocyte reactive antiserum. A sixth patient, whose blast cells were anti-ALL negative (ALL-) at presentation, subsequently developed central nervous system leukaemia with anti-ALL positive (ALL+) blast cells in the CSF. In all cases the leukaemic blast cells showed greatly diminished expression of cholera toxin receptors when compared to granulocytic cells from the chronic phase of CML. This parallels weak or negligible expression of the cholera toxin receptor in ALL and AML. These results suggest that the blastic phase of CML may involve different cellular derivatives of a pluripotential stem cell in which the primary malignant/genetic changes reside. The blast crisis of CML can therefore be heterogeneous with respect to cellular expression and in a significant proportion of patients involves a cell which is by membrane markers and morphological criteria indistinguishable from that seen in the common form of ALL. In these cases the Philadelphia chromosome may be the only distinguishing cellular characteristic. | lld:pubmed |
| pubmed-article:788772 | pubmed:language | eng | lld:pubmed |
| pubmed-article:788772 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:788772 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:788772 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:788772 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:788772 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:788772 | pubmed:issn | 0007-1048 | lld:pubmed |
| pubmed-article:788772 | pubmed:author | pubmed-author:BeardM EME | lld:pubmed |
| pubmed-article:788772 | pubmed:author | pubmed-author:JanossyGG | lld:pubmed |
| pubmed-article:788772 | pubmed:author | pubmed-author:CatovskyDD | lld:pubmed |
| pubmed-article:788772 | pubmed:author | pubmed-author:RobertsMM | lld:pubmed |
| pubmed-article:788772 | pubmed:author | pubmed-author:GreavesM FMF | lld:pubmed |
| pubmed-article:788772 | pubmed:author | pubmed-author:ListerT ATA | lld:pubmed |
| pubmed-article:788772 | pubmed:author | pubmed-author:KirkBB | lld:pubmed |
| pubmed-article:788772 | pubmed:author | pubmed-author:DurrantJJ | lld:pubmed |
| pubmed-article:788772 | pubmed:author | pubmed-author:ReveszTT | lld:pubmed |
| pubmed-article:788772 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:788772 | pubmed:volume | 34 | lld:pubmed |
| pubmed-article:788772 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:788772 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:788772 | pubmed:pagination | 179-92 | lld:pubmed |
| pubmed-article:788772 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:788772 | pubmed:meshHeading | pubmed-meshheading:788772-H... | lld:pubmed |
| pubmed-article:788772 | pubmed:meshHeading | pubmed-meshheading:788772-L... | lld:pubmed |
| pubmed-article:788772 | pubmed:meshHeading | pubmed-meshheading:788772-E... | lld:pubmed |
| pubmed-article:788772 | pubmed:meshHeading | pubmed-meshheading:788772-C... | lld:pubmed |
| pubmed-article:788772 | pubmed:meshHeading | pubmed-meshheading:788772-L... | lld:pubmed |
| pubmed-article:788772 | pubmed:meshHeading | pubmed-meshheading:788772-V... | lld:pubmed |
| pubmed-article:788772 | pubmed:meshHeading | pubmed-meshheading:788772-F... | lld:pubmed |
| pubmed-article:788772 | pubmed:meshHeading | pubmed-meshheading:788772-C... | lld:pubmed |
| pubmed-article:788772 | pubmed:meshHeading | pubmed-meshheading:788772-I... | lld:pubmed |
| pubmed-article:788772 | pubmed:year | 1976 | lld:pubmed |
| pubmed-article:788772 | pubmed:articleTitle | Blast crisis of chronic myeloid leukaemia (CML). II. Cell surface marker analysis of "lymphoid" and myeloid cases. | lld:pubmed |
| pubmed-article:788772 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:788772 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:788772 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:788772 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:788772 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:788772 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:788772 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:788772 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:788772 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:788772 | lld:pubmed |
